H2020FP7HORIZON
Centre Hospitalier Regional et Universitaire de Lille
- Country
- FRFrance
- Defence projects
- 0
- Projects, all programmes
- 32
- As coordinator
- 2
- EU contribution (CORDIS)
- EUR 12,763,533
- Active
- 2008 to 2025
Projects
32 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| H2020MM04DC-based immunotherapy to treat Malignant Mesothelioma | H2020 | 2016 | Participant | EUR 659,823 |
| RHAPSODYAssessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881 | H2020 | 2016 | Participant | EUR 299,296 |
| HBP SGA1Human Brain Project Specific Grant Agreement 1 | H2020 | 2016 | Participant | EUR 0 |
| FAIR-PARK-IIConservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone | H2020 | 2015 | Coordinator | EUR 2,604,800 |
| MON4STRATTherapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance | FP7 | 2014 | Participant | EUR 251,092 |
| DIRECTDIabetes REsearCh on patient sTratification | FP7 | 2012 | Participant | EUR 201,071 |
| NILVADA European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease | FP7 | 2012 | Participant | EUR 427,635 |
| EUROHYP-1European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke | FP7 | 2012 | Participant | EUR 303,041 |
| PEVNETPersistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise | FP7 | 2011 | Participant | EUR 348,000 |
| MITOTARGETMitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics | FP7 | 2009 | Participant | EUR 73,201 |
| PSIPPATIENT SAFETY THROUGH INTELLIGENT PROCEDURES IN MEDICATION | FP7 | 2008 | Coordinator | EUR 1,538,384 |
| LOULLA&PHILLADevelopment of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children | FP7 | 2008 | Participant | EUR 47,895 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.